8-K
Foghorn Therapeutics Inc. (FHTX)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
| ________________________ |
|---|
FORM 8-K
| ________________________________________________________________________________________________ |
|---|
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): August 9, 2023
| ________________________________________________________________________________________________ |
|---|
Foghorn Therapeutics Inc.
(Exact name of registrant as specified in its charter)
| ________________________________________________________________________________________________ | | --- || Delaware | 001-39634 | 47-5271393 | | --- | --- | --- | | (State or other jurisdiction of incorporation) | (Commission<br><br>File Number) | (IRS Employer Identification No.) || 500 Technology Square, Ste 700 | | | | | --- | --- | --- | --- | | | Cambridge, | MA | 02139 | | (Address of principal executive offices) | | | (Zip Code) |
(Registrant’s telephone number, including area code): (617) 586-3100
Not Applicable
(Former name or former address, if changed since last report)
| ________________________ |
|---|
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| ☐ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|---|---|
| ☐ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| --- | --- |
| ☐ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| --- | --- |
| ☐ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
| --- | --- |
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading<br><br>Symbol(s) | Name of each exchange<br><br>on which registered |
|---|---|---|
| Common Stock, $0.0001 par value per share | FHTX | The Nasdaq Global Market |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☒
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 1.02 Termination of a Material Definitive Agreement
On August 9, 2023, Foghorn Therapeutics Inc. (the “Company”) received notice from Merck Sharp & Dohme Corp. (“Merck”) that Merck is terminating the Research Collaboration and Exclusive License Agreement between the Company and Merck, dated as of July 2, 2020 (the “Agreement”). The termination of the Agreement will be effective as of November 7, 2023.
Under the Agreement, the Company granted Merck exclusive global rights to develop, manufacture and commercialize drugs that target dysregulation of a single transcription factor. The Company has been informed by Merck that the decision to terminate the Agreement was the result of an internal portfolio prioritization decision. The Company received a total of $20 million from Merck under the Agreement.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| FOGHORN THERAPEUTICS INC. | |
|---|---|
| By: | /s/ Allan Reine |
| Allan Reine, M.D. | |
| Chief Financial Officer |
Date: August 10, 2023